The No Passes for Polluters Act of 2026 requires Congress to explicitly approve any exemptions from Clean Air Act regulations before the President or federal agencies can use them. Under this bill, the President must submit a detailed message to both houses of Congress explaining the reasons and facts behind any proposed exemption, which then triggers a special legislative process. To pass such an exemption, a joint resolution must be approved by a two-thirds vote in both the Senate and the House of Representatives, with limited debate and no amendments allowed. Additionally, the Comptroller General will review these proposals to ensure they have legal authority, and any unauthorized use of exemptions could lead to civil lawsuits. The legislation also mandates that the President reconsider certain executive branch emissions regulations every three years.
The Americans vs. Poisonous Pesticides Act amends federal pesticide laws to allow state courts to hear lawsuits alleging that pesticide labels fail to warn about health or environmental risks. It clarifies that a pesticide's federal registration and label approval do not automatically block these state claims, though they serve as initial evidence of compliance. The bill also permits companies to update their product labels to address new safety information without waiting for prior government approval, subject to potential review by the agency. These changes apply to both new lawsuits and cases already in progress, ensuring that federal rules do not limit existing state legal remedies for damages or injunctive relief.
This bill would establish the Julius Rosenwald and Rosenwald Schools National Historical Park, a unit of the National Park System, to honor philanthropist Julius Rosenwald and the Rosenwald Schools that educated over 600,000 African American children in the segregated South from 1912 to 1932. The park would include three restored schools (in Maryland, South Carolina, and Virginia) and a visitor center in Chicago, Illinois, to preserve these sites and share their history through exhibits and educational programs. It also creates a national network to connect remaining Rosenwald Schools, enabling coordinated interpretation and resource-sharing across the country.
This bill limits how many patents brand-name drug companies can use to block generic versions of biological drugs (biologics). It caps the number of patents a brand company can assert in lawsuits against generic manufacturers at 20, with no more than 10 being patents issued after a specified date. Courts may allow more patents only in specific cases, such as if the generic company fails to provide required information or if there are material changes to the product. The law applies to new applications submitted after enactment and aims to reduce patent-related delays for cheaper generic biologics.
HR 6529, the Protecting Families from AI Data Center Energy Costs Act, mandates the Federal Energy Regulatory Commission (FERC) to hold a technical conference within 90 days of enactment. The conference will include AI data centers, utilities, and ratepayer advocates to develop strategies protecting residential and small commercial customers from rising energy costs caused by large energy users. FERC must then submit a report with recommendations to Congress within 180 days. This procedural bill directly affects households and small businesses facing potential rate increases due to AI data center energy demands.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
This bill establishes the INCLUDE Project at the National Institutes of Health (NIH) to advance research on Down syndrome and related health conditions. It requires NIH to fund high-risk studies on trisomy 21, support inclusive clinical trials for people with Down syndrome across all ages, and investigate co-occurring conditions like Alzheimer’s disease and autoimmunity. The law mandates NIH coordination across its institutes, consultation with patient advocates, and biennial reports to Congress detailing funded research and its real-world applications. The project directly affects individuals with Down syndrome, their families, and medical researchers, aiming to improve diagnosis, treatment, and quality of life through targeted scientific efforts.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.
The Judicial Integrity Act amends federal law to clarify how financial conflicts of interest apply to judges and Supreme Court justices. It requires that any financial interests held by these officials be evaluated against a new regulatory exemption process managed by the Judicial Conference. Under this bill, a financial interest can only be considered too small to matter if the Judicial Conference issues a public rule explicitly exempting it after a notice and comment period. This change ensures that exemptions are formalized through official regulations rather than being assumed without review.
The Judicial FOIA Expansion Act requires federal courts to release specific records to the public under the Freedom of Information Act. This law mandates the disclosure of attorney disciplinary actions, complaints against judges, meeting minutes, jury selection forms, and performance reports, while explicitly excluding information about ongoing cases. The bill also directs courts to provide this data in machine-readable formats and authorizes $10 million in funding to establish an office within the Administrative Office of the United States Courts to manage these requirements.
